Abstract
The aim of this chapter is to show how immune cells participate in the pathogenesis of type 2 diabetes (T2D). Obesity is a major T2D driver and it is also associated with insulin resistance (IR). These pathologies appear along with chronic inflammation characterized by an increased expression of proinflammatory molecules such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1β, resistin, and leptin, whereas anti-inflammatory cytokines as adiponectin, IL-4, IL-10, and IL-1Ra are decreased. The inflammatory response is triggered, and it occurs predominantly in adipose tissue (AT). Immune cells that secrete many inflammatory effectors related to T2D are macrophages, lymphocytes T and B-2, natural killer (NK), Th1, Th2, Th17, T regulatory, invariant (i)NKT, eosinophils, dendritic (DC), and mast cells. In obesity conditions, macrophage AT population shifts from M2 to the M1 type, the first express anti-inflammatory and the last express proinflammatory cytokines; moreover a decreased frequency of DC has been observed on AT. Mast cells in the presence of high glucose levels express proinflammatory cytokines. Proinflammatory γδ T, Th1, and CD8+ T cells increased in response to a high-fat diet (HFD) in mice, and they are concomitant with a low abundance of anti-inflammatory NK, Th2, and Treg cells, especially in visceral AT (VAT). The same effect was observed on subjects with morbid obesity as they also exhibit a selective increase of Th CD4+ cells. Finally, we will describe some strategies designed to inhibit or decrease the deleterious inflammatory effects caused by adipocytes and immune cells in human T2D.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
In the following references, you can find additional information about alterations of immune cells from adipose tissue during the development of type 2 diabetes, that are treated in the present chapter.
References
Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127:1–4.
Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat Rev Immunol. 2019;19:734–46.
Shuwa HA, Dallatu MK, Yeldu MH, Ahmed HM, Nasir IA. Effects of adalimumab, an anti-tumour necrosis factor-alpha (TNF-alpha) antibody, on obese diabetic rats. Malay J Med Sci. 2018;25:51–62.
Jörns A, Arndt T, Yamada S, Ishikawa D, Yoshimoto T, Terbish T, et al. Translation of curative therapy concepts with T cell and cytokine antibody combinations for type 1 diabetes reversal in the IDDM rat. J Mol Med. 2020;98:1125–37.
Stenkula KG, Erlanson-Albertsson C. Am J Phys Regul Integr Comp Phys. 2018;315:R284–95.
Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133–223.
Han L, Liu J, Zhu L, Tan F, Qin Y, Huang H, et al. Free fatty acid can induce cardiac dysfunction and alter insulin signaling pathways in the heart. Lipids Health Dis. 2018;17:185.
Suiter C, Singha SK, Khalili R, Shariat-Madar Z. Free fatty acids: circulating contributors of metabolic syndrome. Cardiovasc Hematol Agents Med Chem. 2018;16:20–34.
Gao W, Du X, Lei L, Wang H, Zhang M, Wang Z, et al. NEFA-induced ROS impaired insulin signalling through the JNK and p38MAPK pathways in non-alcoholic steatohepatitis. J Cell Mol Med. 2018;22:3408–22.
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of underlying molecular mechanisms. J Cell Physiol. 2019;234:8152–61.
Lu L, Ye X, Yao Q, Lu A, Zhao Z, Ding Y, et al. Egr2 enhances insulin resistance via JAK2/STAT3/SOCS-1 pathway in HepG2 cells treated with palmitate. Gen Comp Endocrinol. 2018;260:25–31.
Pedroso JAB, Ramos-Lobo AM, Donato J Jr. SOCS3 as a future target to treat metabolic disorders. Hormones. 2019;18:127–36.
Kuryłowicz A, Puzianowska-Kuźnicka M. Induction of adipose tissue browning as a strategy to combat obesity. Int J Mol Sci. 2020;21:6241.
Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia. 2007;50:1127–39.
Hill JH, Solt C, Foster MT. Obesity associated disease risk: the role of inherent differences and location of adipose depots. Horm Mol Biol Clin Invest. 2018;33:20180012.
Li J, Wu H, Liu Y, Yang L. High fat diet induced obesity model using four strains of mice: Kunming, C57BL/6, BALB/c and ICR. Exp Anim. 2020;69:326–35.
Wensveen FM, Jelencic V, Valentic S, Sestan M, Wensveen TT, Theurich S, Glasner A, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol. 2015;16:376–85.
Albert V, Svensson K, Shimobayashi M, Colombi M, Muñoz S, Jimenez V, et al. mTORC2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue. EMBO Mol Med. 2016;8:232–46.
Tews D, Pula T, Funcke JB, Jastroch M, Keuper M, Debatin KM, et al. Elevated UCP1 levels are sufficient to improve glucose uptake in human white adipocytes. Redox Biol. 2019;26:101286.
Søndergaard E, Nielsen S. VLDL triglyceride accumulation in skeletal muscle and adipose tissue in type 2 diabetes. Curr Opin Lipidol. 2018;29(1):42–7.
Zou Y, Sheng G, Yu M, Xie G. The association between triglycerides and ectopic fat obesity: an inverted U-shaped curve. PLoS One. 2020;15(11):e0243068.
Oh YS, Bae GD, Baek DJ, Park EY, Jun HS. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol. 2018;9:384.
Kim K, Kwak MK, Bae GD, Park EY, Baek DJ, Kim CY, Jang SE, Jun HS, Oh YS. Allomyrina dichotoma larva extract attenuates free fatty acid-induced lipotoxicity in pancreatic beta cells. Nutr Res Pract. 2021;15:294–308.
Tomášová P, Čermáková M, Pelantová H, Vecka M, Kratochvílová H, Lipš M, et al. Lipid profiling in epicardial and subcutaneous adipose tissue of patients with coronary artery disease. J Proteome Res. 2020;19:3993–4003.
Toczylowski K, Hirnle T, Harasiuk D, Zabielski P, Lewczuk A, Dmitruk I, et al. Plasma concentration and expression of adipokines in epicardial and subcutaneous adipose tissue are associated with impaired left ventricular filling pattern. J Transl Med. 2019;17:310.
Saxton SN, Withers SB, Nyvad J, Mazur A, Matchkov V, Heagerty AM, et al. Perivascular adipose tissue contributes to the modulation of vascular tone in vivo. J Vasc Res. 2019;56:320–32.
Jovanovic K, Siebeck M, Gropp R. The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells. Clin Exp Immunol. 2014;178:201–11.
Watanabe M, Toyomura T, Tomiyama M, Wake H, Liu K, Teshigawara K, et al. Advanced glycation end products (AGEs) synergistically potentiated the proinflammatory action of lipopolysaccharide (LPS) and high mobility group box-1 (HMGB1) through their direct interactions. Mol Biol Rep. 2020;47(9):7153–9.
Ponte-Negretti CI, Wyss FS, Piskorz D, Santos RD, Villar R, Lorenzatti A, et al. Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Arch Cardiol Mex. 2021;92:99.
de Matos MA, Garcia BCC, Vieira DV, de Oliveira MFA, Costa KB, Aguiar PF, et al. High-intensity interval training reduces monocyte activation in obese adults. Brain Behav Immun. 2019;80:818–24.
SahBandar IN, Ndhlovu LC, Saiki K, Kohorn LB, Peterson MM, D’Antoni ML, et al. Relationship between circulating inflammatory monocytes and cardiovascular disease measures of carotid intima thickness. J Atheroscler Thromb. 2020;27:441–8.
Cruz L, Garcia-Macedo R, Garcia-Valerio Y, Gutierrez M, Medina-Navarro R, Duran G, Wacher N, Kumate J. low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care. 2004;27:1451–3.
Chen T, Tu M, Huang L, Zheng Y. Association of serum adiponectin with intima media thickness of dorsalis pedis artery and macroangiopathy in type 2 diabetes. J Diabetes Res. 2020;2020:4739271.
Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013;17:851–9.
Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000;343:338–44.
Delves PJ, Roitt D. The immune system–first of two parts. N Engl J Med. 2000;343:37–50.
Purcell AW, Ramarathinam SH, Ternette N. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat Protoc. 2019;14(6):1687–707.
Dendrou CA, Petersen J, Rossjohn J, Fugger L. HLA variation and disease. Nat Rev Immunol. 2018;18:325–39.
McLaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest. 2017;127:5–13.
Grant R, Youm YH, Ravussin A, Dixit VD. Quantification of adipose tissue leukocytosis in obesity. Methods Mol Biol. 2013;1040:195–209.
Sárvári AK, Van Hauwaert EL, Markussen LK, Gammelmark E, Marcher AB, Ebbesen MF, et al. Plasticity of epididymal adipose tissue in response to diet-induced obesity at single-nucleus resolution. Cell Metab. 2021;33:437–53.e5.
Liu L, Inouye KE, Allman WR, Coleman AS, Siddiqui S, Hotamisligil GS, et al. TACI-deficient macrophages protect mice against metaflammation and obesity-induced dysregulation of glucose homeostasis. Diabetes. 2018;67:1589–603.
Wara AK, Wang S, Wu C, Fang F, Haemmig S, Weber BN, et al. KLF10 Deficiency in CD4(+) T cells triggers obesity, insulin resistance, and fatty liver. Cell Rep. 2020;33:108550.
Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123–47.
Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11:738–49.
Kumar D, Shankar K, Patel S, Gupta A, Varshney S, Gupta S, et al. Chronic hyperinsulinemia promotes meta-inflammation and extracellular matrix deposition in adipose tissue: implications of nitric oxide. Mol Cell Endocrinol. 2018;477:15–28.
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:75–184.
McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014;41:36–48.
Kumar D, Pandya SK, Varshney S, Shankar K, Rajan S, Srivastava A, et al. Temporal immunometabolic profiling of adipose tissue in HFD-induced obesity: manifestations of mast cells in fibrosis and senescence. Int J Obes. 2019;43:1281–94.
Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes. 2009;58:2574–82.
Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, et al. Pro-inflammatory CD11cCCD206C adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes. 2010;59:1648–56.
Hu L, He F, Huang M, Peng M, Zhou Z, Liu F, et al. NFATc3 deficiency reduces the classical activation of adipose tissue macrophages. J Mol Endocrinol. 2018;61:79–89.
Kotnik P, Keuper M, Wabitsch M, Fischer-Posovszky P. Interleukin-1β downregulates RBP4 secretion in human adipocytes. PLoS One. 2013;8:e57796. https://doi.org/10.1371/journal.pone.0057796.
Constant VA, Gagnon A, Landry A, Sorisky A. Macrophage-conditioned medium inhibits the differentiation of 3T3-L1 and human abdominal preadipocytes. Diabetologia. 2006;49:1402–11.
Engin A. Adipose tissue hypoxia in obesity and its impact on preadipocytes and macrophages: hypoxia hypothesis. Adv Exp Med Biol. 2017;960:305–26.
Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, et al. Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab. 2012;15:518–33.
Reidy PT, Yonemura NM, Madsen JH, McKenzie AI, Mahmassani ZS, Rondina MT, et al. An accumulation of muscle macrophages is accompanied by altered insulin sensitivity after reduced activity and recovery. Acta Physiol. 2019;226:e13251.
He W, Yuan T, Maedler K. Macrophage-associated pro-inflammatory state in human islets from obese individuals. Nutr Diab. 2019;9:36.
Kiran S, Kumar V, Kumar S, Price RL, Singh UP. Adipocyte, immune cells, and miRNA crosstalk: a novel regulator of metabolic dysfunction and obesity. Cells. 2021;10:1004.
Abdel-Hamid AAM, Firgany AEL. Correlation between pancreatic mast cells and the low grade inflammation in adipose tissue of experimental prediabetes. Acta Histochem. 2019;121:35–42.
Yabut JM, Desjardins EM, Chan EJ, Day EA, Leroux JM, Wang B, et al. Genetic deletion of mast cell serotonin synthesis prevents the development of obesity and insulin resistance. Nat Commun. 2020;11(1):463.
Żelechowska P, Agier J, Kozłowska E, Brzezińska-Błaszczyk E. Mast cells participate in chronic low-grade inflammation within adipose tissue. Obes Rev. 2018;19:686–97.
Gutierrez DA, Muralidhar S, Feyerabend TB, Herzig S, Rodewald HR. Hematopoietic kit deficiency, rather than lack of mast cells, protects mice from obesity and insulin resistance. Cell Metab. 2015;21:678–91.
Chmelar J, Chatzigeorgiou, Kyoung-Jin C, Prucnal M, Voehringer D, Roers, et al. No role for mast cells in obesity-related metabolic dysregulation. Front Immunol. 2016;7:524.
Yoon J, Um HN, Jang J, Bae YA, Park WJ, Kim HJ, et al. Eosinophil activation by toll-like receptor 4 ligands regulates macrophages polarization. Front Cell Dev Biol. 2019;7:329.
Kohlgruber AC, Gal-Oz ST, LaMarche NM, Shimazaki M, Duquette D, Koay HF, et al. gammadelta T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. Nat Immunol. 2018;19:464–74.
Li Y, Woods K, Parry-Strong A, Anderson RJ, Capistrano C, Gestin A, et al. Distinct dysfunctional states of circulating innate-like t cells in metabolic disease. Front Immunol. 2020;11:448.
Van Herck MA, Weyler J, Kwanten WJ, Dirinck EL, De Winter BY, Francque SM, et al. The differential roles of T cells in non-alcoholic fatty liver disease and obesity. Front Immunol. 2019;10:82.
Rampoldi F, Ullrich L, Prinz I. Revisiting the interaction of gammadelta T-cells and B-cells. Cells. 2020;9:743.
Guo H, Xu BC, Yang XG, Peng D, Wang Y, Liu XB, et al. A high frequency of peripheral blood IL-22(+) CD4(+) T cells in patients with new onset type 2 diabetes mellitus. J Clin Lab Anal. 2016;30:95–102.
Goldberg EL, Shchukina I, Asher JL, Sidorov S, Artyomov MN, Dixit VD. Ketogenesis activates metabolically protective gammadelta T cells in visceral adipose tissue. Nat Metab. 2020;2:50–61.
Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921–9.
Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, et al. Obesity predisposes to Th17 bias. Eur J Immunol. 2009;39:2629–35.
Tao L, Liu H, Gong Y. Role and mechanism of the Th17/Treg cell balance in the development and progression of insulin resistance. Mol Cell Biochem. 2019;459:183–8.
Mogilenko DA, Caiazzo R, L’homme L, Pineau L, Raverdy V, Noulette J, et al. IFNgamma-producing NK cells in adipose tissue are associated with hyperglycemia and insulin resistance in obese women. Int J Obes. 2021;45:1607–17.
Wu L, Parekh VV, Gabriel CL, Bracy DP, Marks-Shulman PA, Tamboli RA, et al. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc Natl Acad Sci U S A. 2012;109:E1143–52.
Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerspach AC, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018;128:1538–50.
Pirola L, Ferraz JC. Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem. 2017;8:120–8.
Talwar H, Bouhamdan M, Bauerfeld C, Talreja J, Aoidi R, Houde N, et al. MEK2 Negatively regulates lipopolysaccharide-mediated IL-1beta production through HIF-1alpha expression. J Immunol. 2019;202:1815–25.
Surendar J, Karunakaran I, Frohberger SJ, Koschel M, Hoerauf A, Hübner MP. Macrophages mediate increased CD8 T cell inflammation during weight loss in formerly obese mice. Front Endocrinol. 2020;11:257.
Mahmoud F, Al-Ozairi E. Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes. Dis Markers. 2013;35:235–41.
Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, Benoist C, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature. 2012;486:549–53.
Xu Z, Wang G, Zhu Y, Liu R, Song J, Ni Y, et al. PPAR-gamma agonist ameliorates liver pathology accompanied by increasing regulatory B and T cells in high-fat-diet mice. Obesity. 2017;25:581–90.
Sandoval H, Kodali S, Wang J. Regulation of B cell fate, survival, and function by mitochondria and autophagy. Mitochondrion. 2018;41:58–65.
Kaminski DA, Randall TD. Adaptive immunity and adipose tissue biology. Trends Immunol. 2010;31:384–90.
Meza-Perez S, Randall TD. Immunological functions of the omentum. Trends Immunol. 2017;38:526–36.
Srikakulapu P, Upadhye A, Drago F, Perry HM, Bontha SV, McSkimming C, et al. Chemokine receptor-6 promotes B-1 cell trafficking to perivascular adipose tissue, local IgM production and atheroprotection. Front Immunol. 2021;12:636013.
Duffaut C, Galitzky J, Lafontan M, Bouloumie A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun. 2009;384:482–5.
Frasca D, Diaz A, Romero M, Vazquez T, Blomberg BB. Obesity induces pro-inflammatory B cells and impairs B cell function in old mice. Mech Ageing Dev. 2017;162:91–9.
Pham TD, Change MY, Roskin KM, Jackson KJL, Nguyen KD, Glanville J, et al. High-fat diet induces systemic B-cell repertoire changes associated with insulin resistance. Mucosal Immunol. 2017;10:1468–79.
Wang Y, Liu J, Burrows PD, Wang JY. B cell development and maturation. Adv Exp Med Biol. 2020;1254:1–22.
Srikakulapu P, Upadhye A, Rosenfeld SM, Marshall MA, McSkimming C, Hickman AW, et al. Perivascular adipose tissue harbors atheroprotective IgM-producing B cells. Front Physiol. 2017;8:719.
Defuria J, Belkina AC, Jagannathan-Bogdan M, Snyder-Cappione J, Carr JD, Nersesova YR, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A. 2013;110:5133–8.
Frasca D, Blomberg BB. Adipose tissue inflammation induces B cell inflammation and decreases B cell function in aging. Front Immunol. 2017;8:1003.
Srikakulapu P, McNamara CA. B lymphocytes and adipose tissue inflammation. Arterioscler Thromb Vasc Biol. 2020;40:1110–22.
Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol. 2013;171:8e19.
O’Rourke RW, Meyer KA, Neeley CK, Gaston GD, Sekhri P, Szumowski M, et al. Systemic NK cell ablation attenuates intra-abdominal adipose tissue macrophage infiltration in murine obesity. Obesity. 2014;22:2109–14.
Theurich S, Tsaousidou E, Hanssen R, Lempradl AM, Mauer J, Timper K, et al. IL-6/Stat3-dependent induction of a distinct, obesity-associated NK cell subpopulation deteriorates energy and glucose homeostasis. Cell Metab. 2017;26:171–84.e6.
Lee J, Dieckmann NMG, Edgar JR, Griffiths GM, Siegel RM. Fas Ligand localizes to intraluminal vesicles within NK cell cytolytic granules and is enriched at the immune synapse. Immun Inflamm Dis. 2018;6:312–21.
Wensveen FM, Jelenčić V, Valentić S, Šestan M, Wensveen TT, Theurich S, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol. 2015;16:376–85.
Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity. 2012;37:574–87.
Huh JY, Park YJ, Kim JB. Adipocyte CD1d determines adipose inflammation and insulin resistance in obesity. Adipocyte. 2018;7:129–36.
Rakhshandehroo M, van Eijkeren RJ, Gabriel TL, de Haar C, Gijzel SMW, Hamers N, et al. Adipocytes harbor a glucosylceramide biosynthesis pathway involved in iNKT cell activation. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:1157–67.
Kim HM, Lee BR, Lee ES, Kwon MH, Huh JH, Kwon BE, et al. iNKT cells prevent obesity-induced hepatic steatosis in mice in a C-C chemokine receptor 7-dependent manner. Int J Obes. 2018;42:270–9.
Subramanian S, Goodspeed L, Wang S, Ding Y, O’Brien KD, Getz GS, et al. Deficiency of invariant natural killer T cells does not protect against obesity but exacerbates atherosclerosis in Ldlr(-/-) mice. Int J Mol Sci. 2018;19:510.
van Eijkeren RJ, Morris I, Borgman A, Markovska A, Kalkhoven E. Cytokine output of adipocyte-iNKT cell interplay is skewed by a lipid-rich microenvironment. Front Endocrinol. 2020;11:479.
López S, García-Serrano S, Gutierrez-Repiso C, Rodríguez-Pacheco F, Ho-Plagaro A, Santiago-Fernandez C, et al. Tissue-specific phenotype and activation of iNKT cells in morbidly obese subjects: interaction with adipocytes and effect of bariatric surgery. Obes Surg. 2018;28:2774–82.
Amon L, Lehmann CHK, Baranska A, Schoen J, Heger L, Dudziak D. Transcriptional control of dendritic cell development and functions. Int Rev Cell Mol Biol. 2019;349:55–151.
Antony A, Lian Z, Perrard XD, Perrard J, Liu H, Cox AR, et al. Deficiency of Stat1 in CD11c(+) cells alters adipose tissue inflammation and improves metabolic dysfunctions in mice fed a high-fat diet. Diabetes. 2021;70:720–32.
Chen Y, Tian J, Tian X, Tang X, Rui K, Tong J, et al. Adipose tissue dendritic cells enhances inflammation by prompting the generation of Th17 cells. PLoS One. 2014;9:e92450.
Zhang J, Chen X, Liu W, Zhang C, Xiang Y, Liu S, et al. Metabolic surgery improves the unbalanced proportion of peripheral blood myeloid dendritic cells and T lymphocytes in obese patients. Eur J Endocrinol. 2021;185:819.
Kojta I, Chacińska M, Błachnio-Zabielska A. Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients. 2020;12:1305.
Ying W, Fu W, Lee YS, Olefsky JM. The role of macrophages in obesity-associated islet inflammation and beta-cell abnormalities. Rev Endocrinol. 2020;16:81–90.
Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233:6425–40.
Nieto-Vazquez I, Fernandez-Veledo S, Kramer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem. 2008;114:183–94.
Vanderford NL. Defining the regulation of IL-1beta- and CHOP-mediated beta-cell apoptosis. Islets. 2010;2:334–6.
Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005;28:2890–5.
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–50.
Qu W, Han C, Li M, Zhang J, Jiang Z. Anti-TNF-alpha antibody alleviates insulin resistance in rats with sepsis-induced stress hyperglycemia. J Endocrinol Invest. 2018;41:455–63.
Lo J, Bernstein LE, Canavan B, Torriani M, Jackson MB, Ahima RS, Grinspoon SK. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2007;293:E102–9.
Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 1998;83:2907–10.
Maekawa M, Tadaki H, Tomimoto D, Okuma C, Sano R, Ishii Y, et al. A novel TNF-alpha converting enzyme (TACE) selective inhibitor JTP-96193 prevents insulin resistance in KK-A(y) type 2 diabetic mice and diabetic peripheral neuropathy in type 1 diabetic mice. Biol Pharm Bull. 2019;42:1906–12.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.
Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of Type 2 diabetes mellitus. J Cell Biochem. 2018;119:105–10.
Alipourfard I, Datukishvili N, Mikeladze D. TNF-alpha downregulation modifies insulin receptor substrate 1 (IRS-1) in metabolic signaling of diabetic insulin-resistant hepatocytes. Mediat Inflamm. 2019;2019:3560819.
Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS. Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes. 2002;51:2929–35.
Xu M, Ge C, Qin Y, Gu T, Lv J, Wang S, et al. Activated TNF-alpha/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: inhibition by dietary fisetin intervention. Food Funct. 2019;10(3):1302–16.
Jung HS, Shimizu-Albergine M, Shen X, Kramer F, Shao D, Vivekanandan-Giri A, et al. TNF-alpha induces acyl-CoA synthetase 3 to promote lipid droplet formation in human endothelial cells. J Lipid Res. 2020;61:33–44.
Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia. 2005;48:1038–50.
Pfeiler S, Winkels H, Kelm M, Gerdes N. IL-1 family cytokines in cardiovascular disease. Cytokine. 2019;122:154215.
Kim DH, Lee B, Lee J, Kim ME, Lee JS, Chung JH, et al. FoxO6-mediated IL-1beta induces hepatic insulin resistance and age-related inflammation via the TF/PAR2 pathway in aging and diabetic mice. Redox Biol. 2019;24:101184.
Ruscitti P, Ursini F, Cipriani P, Greco M, Alvaro S, Vasiliki L, et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: an observational study. Medicine. 2019;98:e14587.
Kursawe R, Dixit VD, Scherer PE, Santoro N, Narayan D, Gordillo R, et al. A role of the inflammasome in the low storage capacity of the abdominal subcutaneous adipose tissue in obese adolescents. Diabetes. 2016;65:610–8.
Arous C, Ferreira PG, Dermitzakis ET, Halban PA. Short term exposure of beta cells to low concentrations of interleukin-1β improves insulin secretion through focal adhesion and actin remodeling and regulation of gene expression. J Biol Chem. 2015;290:6653–69.
Hajmrle C, Smith N, Spigelman AF, Dai X, Senior L, Bautista A, et al. Interleukin-1 signaling contributes to acute islet compensation. JCI Insight. 2016;1:e86055.
Nordmann TM, Dror E, Schulze F, Traub S, Berishvili E, Barbieux C, et al. The role of inflammation in beta-cell dedifferentiation. Sci Rep. 2017;7:6285.
Ghiasi SM, Dahllöf MS, Osmai Y, Osmai M, Jakobsen KK, Aivazidis A, et al. Regulation of the beta-cell inflammasome and contribution to stress-induced cellular dysfunction and apoptosis. Mol Cell Endocrinol. 2018;478:106–14.
Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020;28:115327.
Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell. 1994;76:241–51.
Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278:45777–84.
Bertholdt L, Gudiksen A, Ringholm S, Pilegaard H. Impact of skeletal muscle IL-6 on subcutaneous and visceral adipose tissue metabolism immediately after high- and moderate-intensity exercises. Pflugers Arch. 2020;472:217–33.
Wueest S, Konrad D. The controversial role of IL-6 in adipose tissue on obesity-induced dysregulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2020;319:E607–13.
Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621–36.
Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200.
Sindhu S, Thomas R, Shihab P, Sriraman D, Behbehani K, Ahmad R. Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation. PLoS One. 2015;10:e0133494.
Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145:2273–82.
Xu E, Pereira MMA, Karakasilioti I, Theurich S, Al-Maarri M, Rappl G, et al. Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance. Nat Commun. 2017;8:14803.
Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018;26:685–98.
Chen X, Gong Q, Wang CY, Zhang K, Ji X, Chen YX, et al. High-fat diet induces distinct metabolic response in interleukin-6 and tumor necrosis factor-alpha knockout mice. J Interf Cytokine Res. 2016;36:580–8.
Whitham M, Pal M, Petzold T, Hjorth M, Egan CL, Brunner JS, et al. Adipocyte-specific deletion of IL-6 does not attenuate obesity-induced weight gain or glucose intolerance in mice. Am J Physiol Endocrinol Metab. 2019;317:E597–604.
Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Estevez E, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21:403–16.
Uciechowski P, Dempke WCM. Interleukin-6: a masterplayer in the cytokine network. Oncology. 2020;98:131–7.
Huang X, Li Y, Fu M, Xin HB. Polarizing macrophages in vitro. Methods Mol Biol. 2018;1784:119–26.
Zhang J, Wu Y, Gao Z. Correlations of C-reactive protein (CRP), interleukin-6 (IL-6), and insulin resistance with cerebral infarction in hypertensive patients. Med Sci Monit. 2019;25:1506–11.
Lowe G, Mark W, Graham H, Ann R, Qiang L, Stephen H, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63:1115–23.
Peppler WT, Townsend LK, Meers GM, Panasevich MR, MacPherson REK, Rector RS, et al. Acute administration of IL-6 improves indices of hepatic glucose and insulin homeostasis in lean and obese mice. Am J Physiol Gastrointest Liver Physiol. 2019;316:G166–78.
Cullen T, Thomas AW, Webb R, Hughes MG. Interleukin-6 and associated cytokine responses to an acute bout of high-intensity interval exercise: the effect of exercise intensity and volume. Appl Physiol Nutr Metab. 2016;41:803–8.
Pinto AP, da Rocha AL, Kohama EB, Gaspar RC, Simabuco FM, Frantz FG, et al. Exhaustive acute exercise-induced ER stress is attenuated in IL-6-knockout mice. J Endocrinol. 2019;240:181–93.
daRocha AL, Pereira BC, Teixeira GR, Pinto AP, Frantz FG, Elias LL, et al. Treadmill slope influences inflammation, changes in the fiber composition, as well as androgen and glucocorticoid receptor expressions in the skeletal muscle of overtrained mice. Front Immunol. 2017;8:1378.
Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil. 2003;24:113–9.
Wedell-Neergaard AS, Lang Lehrskov L, Christensen RH, Legaard GE, Dorph E, Larsen MK, et al. Exercise-induced changes in visceral adipose tissue mass are regulated by IL-6 signaling: a randomized controlled trial. Cell Metab. 2019;29:844–55.e3.
Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and disease. Int J Mol Sci. 2019;20:649.
Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med. 2006;12:65–6.
Hohenester S, Kanitz V, Schiergens T, Einer C, Nagel J, Wimmer R, et al. IL-18 but Not IL-1 Signaling is pivotal for the initiation of liver injury in murine non-alcoholic fatty liver disease. Int J Mol Sci. 2020;21:8602.
Zaharieva E, Kamenov Z, Velikova T, Tsakova A, El-Darawish Y, Okamura H. Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes. Endocr Connect. 2018;7:179–85.
Maravilla Domínguez MA, Zermeño González ML, Zavaleta Muñiz ER, Montes Varela VA, Irecta Nájera CA, Fajardo Robledo NS, et al. Inflammation and atherogenic markers in patients with type 2 diabetes mellitus. Clin Invest Arteriosc. 2021;34:105–12.
Bankul A, Mitra P, Suri S, Saxena I, Shukla R, Shukla K, et al. Increased serum IL-18 levels and IL-18R expression in newly diagnosed type 2 diabetes mellitus. Minerva Endocrinol. 2020;
Ahmad R, Thomas R, Kochumon S, Sindhu S. Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity. Immun Inflamm Dis. 2017;5:318–35.
Gateva A, Kamenov Z, Karamfilova V, Assyov Y, Velikova T, El-Darawish Y, et al. Higher levels of IL-18 in patients with prediabetes compared to obese normoglycaemic controls. Arch Physiol Biochem. 2020;126:449–52.
Liu SY, Chen J, Li YF. Clinical significance of serum interleukin-8 and soluble tumor necrosis factor-like weak inducer of apoptosis levels in patients with diabetic nephropathy. J Diab Invest. 2018;9:1182–8.
Angelova P, Kamenov Z, Tsakova A, El-Darawish Y, Okamura H. Interleukin-18 and testosterone levels in men with metabolic syndrome. Aging Male. 2018;21:130–7.
Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrières J, Amouyel P, et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453–9.
Åkerblom A, James SK, Lakic TG, Becker RC, Cannon CP, Steg PG, PLATO Investigators. Interleukin-18 in patients with acute coronary syndromes. Clin Cardiol. 2019;42:1202–9.
Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, Lee MK, Lawlor KE, et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab. 2016;23:155–64.
Tran DQ. TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J Mol Cell Biol. 2012;4:29–37.
Morikawa M, Derynck R, Miyazono K. TGF-beta and the TGF-beta Family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol. 2016;8:a021873.
Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007;26:579–91.
Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-beta: from conception to autoimmunity and infection. Cold Spring Harb Perspect Biol. 2017;9:a022236.
Zhao B, Xu S, Dong X, Lu C, Springer TA. Prodomain-growth factor swapping in the structure of pro-TGF-beta1. J Biol Chem. 2018;293:1579–89.
Herder C, Zierer A, Koening W, Roden M, Meisinger C, Thorand B. Transforming growth factor-beta1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care. 2009;32:1921–3.
Lee JH, Mellado-Gil JM, Bahn YJ, Pathy SM, Zhang YE, Rane SG. Protection from beta-cell apoptosis by inhibition of TGF-beta/Smad3 signaling. Cell Death Dis. 2020;11:184.
Yadav H, Devalaraja S, Chung ST, Rane SG. TGF-beta1/Smad3 pathway targets PP2A-AMPK-FoxO1 signaling to regulate hepatic gluconeogenesis. J Biol Chem. 2017;292:3420–32.
Acquarone E, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: a reappraisal. Mech Ageing Dev. 2019;178:46–63.
Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:624–30.
Rawal K, Purohit KM, Patel TP, Karont N, Gupta S. Resistin mitigates stemness and metabolic profile of human adipose-derived mesenchymal stem cells via insulin resistance. Cytokine. 2021;138:155374.
Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J. 2020;287:3141–9.
Lazar MA. Resistin- and obesity-associated metabolic diseases. Horm Metab Res. 2007;39:710–6.
Liu SX, Zheng F, Xie KL, Xie MR, Jiang LJ, Cai Y. Exercise reduces insulin resistance in type 2 diabetes mellitus via mediating the lncRNA MALAT1/MicroRNA-382-3p/resistin axis. Mol Ther Nucl Acids. 2019;18:34–44.
Zayani N, Hamdouni H, Boumaiza I, Achour O, Neffati F, Omezzine A, et al. Resistin polymorphism, plasma resistin levels and obesity in Tunisian volunteers. J Clin Lab Anal. 2018;32:e22227.
Wijetunge S, Ratnayake RMCJ, Kotakadeniya HMSRB, Rosairo S, Lbracht-Schulte K, Ramalingam L, et al. Association between serum and adipose tissue resistin with dysglycemia in South Asian women. Nutr Diab. 2019;9:5.
Christou KA, Christou GA, Karamoutsios A, Vartholomatos G, Gartzonika K, Tsatsoulis A, et al. The regulation of serum resistin levels in metabolically healthy and unhealthy obese individuals. Hormones. 2020;19:523–9.
Onalan E, Yakar B, Barım AO, Gursu MF. Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome. Endocrynol Pol. 2020;71:319–24.
Zou CC, Liang L, Hong F, Zhao ZY. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. Endocr J. 2005;52:519–24.
Zurita-Cruz JN, Medina-Bravo P, Manuel-Apolinar L, Damasio-Santana L, Wakida-Kusunoki G, Padilla-Rojas M, et al. Resistin levels are not associated with obesity in central precocious puberty. Peptides. 2018;109:9–13.
Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care. 2009;32(2):329–34.
Kapłon-Cieślicka A, Tymińska A, Rosiak M, Ozierański K, Peller M, Eyileten C, et al. Resistin is a prognostic factor for death in type 2 diabetes. Diabetes Metab Res Rev. 2019;35:e3098.
Zuniga MC, Raghuraman G, Hitchner E, Weyand C, Robinson W, Zhou W. PKC-epsilon and TLR4 synergistically regulate resistin-mediated inflammation in human macrophages. Atherosclerosis. 2017;259:51–9.
Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC, et al. Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. J Cell Physiol. 2011;226:2181–8.
Luo J, Huang L, Wang A, Liu Y, Cai R, Li W, et al. Corrigendum: Resistin-induced endoplasmic reticulum stress contributes to the impairment of insulin signaling in endothelium. Front Pharmacol. 2018;9:1446.
Sabry MM, Dawood AF, Rashed LA, Sayed SM, Hassan S, Younes SF. Relation between resistin, PPAR-gamma, obesity and atherosclerosis in male albino rats. Arch Physiol Biochem. 2020;126:389–98.
Wang LK, Wang H, Wu XL, Shi L, Yang RM, Wang YC. Relationships among resistin, adiponectin, and leptin and microvascular complications in patients with type 2 diabetes mellitus. J Int Med Res. 2020;48:300060519870407.
Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI, et al. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010;14:1419–31.
Avtanski D, Chen K, Poretsky L. Resistin and adenylyl cyclase-associated protein 1 (CAP1) regulate the expression of genes related to insulin resistance in BNL CL.2 mouse liver cells. Data Brief. 2019;25:104112.
Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin. 2018;39:1176–88.
Maurya R, Bhattacharya P, Dey R, Nakhasi HL. Leptin functions in infectious diseases. Front Immunol. 2018;9:2741.
Schepers J, Gebhardt C, Bracke A, Eiffler I, von Bohlen Und Halbach O. Structural and functional consequences in the amygdala of leptin-deficient mice. Cell Tissue Res. 2020;382:421–6.
Lucka A, Wysokiński A. Association between adiposity and fasting serum levels of appetite-regulating peptides: leptin, neuropeptide Y, desacyl ghrelin, peptide YY(1-36), obestatin, cocaine and amphetamine-regulated transcript, and agouti-related protein in nonobese participants. Chin J Physiol. 2019;62:217–25.
Wang P, Loh KH, Wu M, Morgan DA, Schneeberger M, Yu X, et al. A leptin-BDNF pathway regulating sympathetic innervation of adipose tissue. Nature. 2020;583:839–44.
Zhao S, Li N, Zhu Y, Straub L, Zhang Z, Wang MY, et al. Partial leptin deficiency confers resistance to diet-induced obesity in mice. Mol Metab. 2020;37:100995.
Peelman F, Zabeau L, Moharana K, Savvides SN, Tavernier J. 20 years of leptin: insights into signaling assemblies of the leptin receptor. J Endocrinol. 2014;223:T9–23.
Di Spiezio A, Sandin ES, Dore R, Müller-Fielitz H, Storck SE, Bernau M, et al. The LepR-mediated leptin transport across brain barriers controls food reward. Mol Metab. 2018;8:13–22.
Hayden MR, Banks WA. Deficient leptin cellular signaling plays a key role in brain ultrastructural remodeling in obesity and type 2 diabetes mellitus. Int J Mol Sci. 2021;22:5427.
Wang B, Chandrasekera PC, Pippin JJ. Leptin- and leptin receptor-deficient rodent models: relevance for human type2 diabetes. Diab Rev. 2014;10:131–45.
Chen SM, Peng YJ, Wang CC, Su SL, Salter DM, Lee HS. Dexamethasone down-regulates osteocalcin in bone cells through leptin pathway. Int J Med Sci. 2018;15:507–16.
Caron A, Lee S, Elmquist JK, Gautron L. Leptin and brain-adipose crosstalks. Nat Rev Neurosci. 2018;19:153–65.
Marques-Oliveira GH, Silva TM, Lima WG, Valadares HMS, Chaves VE. Insulin as a hormone regulator of the synthesis and release of leptin by white adipose tissue. Peptides. 2018;106:49–58.
Liu J, Yang X, Yu S, Zheng R. The leptin resistance. Adv Exp Med Biol. 2018;1090:145–63.
Coppola A, Capuani B, Pacifici F, Pastore D, Arriga R, Bellia A, et al. Activation of peripheral blood mononuclear cells and leptin secretion: new potential role of interleukin-2 and high mobility group box (HMGB)1. Int J Mol Sci. 2021;22:7988.
Pan WW, Myers MG Jr. Leptin and the maintenance of elevated body weight. Nat Rev Neurosci. 2018;19:95–105.
Sánchez-Margalet V, Martín-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol. 2003;133:11–9.
Zarkesh-Esfahani H, Pockley AG, Wu Z, Hellewell PG, Weetman AP, Ross RJ. Leptin indirectly activates human neutrophils via induction of TNF-alpha. J Immunol. 2004;172:1809–14.
Oswald J, Büttner M, Jasinski-Bergner S, Jacobs R, Rosenstock P, Kielstein H. Leptin affects filopodia and cofilin in NK-92 cells in a dose- and time-dependent manner. Eur J Histochem. 2018;62:2848.
Souza-Almeida G, D’Avila H, Almeida PE, Luna-Gomes T, Liechocki S, Walzog B, et al. Leptin mediates in vivo neutrophil migration: involvement of tumor necrosis factor-alpha and CXCL1. Front Immunol. 2018;9:111.
Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093–103.
Wang M, Wei J, Li H, Ouyang X, Sun X, Tang Y, et al. Leptin upregulates peripheral CD4(+)CXCR5(+)ICOS(+) T cells via increased IL-6 in rheumatoid arthritis patients. J Interf Cytokine Res. 2018;38:86–92.
Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab. 2002;87:1184–8.
Bruun JM, Pedersen SB, Kristensen K, Richelsen B. Effects of proinflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol. 2002;190:91–9.
Lee E, Miedzybrodzka EL, Zhang X, Hatano R, Miyamoto J, Kimura I, et al. Diet-induced obese mice and leptin-deficient Lep(ob/ob) mice exhibit increased circulating GIP levels produced by different mechanisms. Int J Mol Sci. 2019;20:4448.
La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4:371–9.
Moraes-Vieira PM, Larocca RA, Bassi EJ, Peron JP, Andrade-Oliveira V, Wasinski F, et al. Leptin deficiency impairs maturation of dendritic cells and enhances induction of regulatory T and Th17 cells. Eur J Immunol. 2014;44:794–806.
Papathanassoglou E, El-Haschimi K, Li XC, Matarese G, Strom T, Mantzoros C. Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol. 2006;176:7745–52.
Tian Z, Sun R, Wei H, Gao B. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun. 2002;298:297–302.
Laue T, Wrann CD, Hoffmann-Castendiek B, Pietsch D, Hübner L, Kielstein H. Altered NK cell function in obese healthy humans. BMC Obes. 2015;2:1.
Lo CK, Lam QL, Yang, Ko KH, Sun L, Ma R, Wang S, et al. Leptin signaling protects NK cells from apoptosis during development in mouse bone marrow. Cell Mol Immunol. 2009;6:353–60.
Volarevic A, Al-Qahtani A, Arsenijevic N, Pajovic C, Lukic ML. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity. 2010;43:255–63.
Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care. 2009;32:421–3.
Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One. 2010;5:e10100.
Lind L, Sundström J, Ärnlöv J. Proteins associated with incident metabolic syndrome in population-based cohorts. Diabetol Metab Syndr. 2021;13:131.
Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–26.
Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A. 2009;106:13998–4003.
Böni-Schnetzler M, Häuselmann SP, Dalmas E, Meier DT, Thienel C, Traub S, et al. beta Cell-specific deletion of the IL 1 receptor antagonist impairs beta cell proliferation and insulin secretion. Cell Rep. 2018;22:1774–86.
Dandona P, Ghanim H, Abuaysheh S, Green K, Dhindsa S, Makdissi A, et al. Exenatide increases IL-1RA concentration and induces Nrf-2-Keap-1-regulated antioxidant enzymes: relevance to beta-cell function. J Clin Endocrinol Metab. 2018;103:1180–7.
Paul WE. Interleukin 4: signaling mechanisms and control of T cell differentiation. CIBA Found Symp. 1997;204:208–16.
Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B, et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 2008;7:485–95.
Hu X, Wang H, Han C, Cao X. Src promotes anti-inflammatory (M2) macrophage generation via the IL-4/STAT6 pathway. Cytokine. 2018;111:209–15.
Lin SY, Yang CP, Wang YY, Hsiao CW, Chen WY, Liao SL, et al. Interleukin-4 improves metabolic abnormalities in leptin-deficient and high-fat diet mice. Int J Mol Sci. 2020;21:4451.
Choi EW, Lee M, Song JW, Kim K, Lee J, Yang J, et al. Fas mutation reduces obesity by increasing IL-4 and IL-10 expression and promoting white adipose tissue browning. Sci Rep. 2020;10:12001.
Chang YH, Ho KT, Lu SH, Huang CN, Shiau MY. Regulation of glucose/lipid metabolism and insulin sensitivity by interleukin-4. Int J Obes. 2012;36:993–8.
Stafeev IS, Michurina SS, Podkuychenko NV, Vorotnikov AV, Menshikov MY, Parfyonova YV. Interleukin-4 restores insulin sensitivity in lipid-induced insulin-resistant adipocytes. Biochemistry. 2018;83:498–506.
Chang YH, Huang CN, Shiau MY. Association of IL-4 receptor gene polymorphisms with high density lipoprotein cholesterol. Cytokine. 2012;59:309–12.
Ho KT, Shiau MY, Chang YH, Chen CM, Yang SC, Huang CN. Association of IL-4 promoter polymorphisms in Taiwanese patients with type 2 diabetes mellitus. Metabolism. 2010;59:1717–22.
Han X, Boisvert WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb Haemost. 2015;113:505–12.
Kyriazi E, Tsiotra PC, Boutati E, Ikonomidis I, Fountoulaki K, Maratou E. Effects of adiponectin in TNF-α, IL-6, and IL-10 cytokine production from coronary artery disease macrophages. Horm Metab Res. 2011;43:537–44.
Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-β and interleukin-10. Immunity. 2008;28:468–76.
Kartika R, Purnamasari D, Pradipta S, Larasati RA, Wibowo H. Impact of low interferon-γ and IL-10 levels on TNF-α and IL-6 production by PHA-induced PBMCs in type 2 Diabetes Mellitus. J Inflamm Res. 2020;13:187–93.
Saraiva M, Vieira P, O’Garra AJ. Biology and therapeutic potential of interleukin-10. Exp Med. 2020;217:e20190418.
Lynch L. Adipose invariant natural killer T cells. Immunology. 2014;142:337–46.
LaMarche NM, Kane H, Kohlgruber AC, Dong H, Lynch L, Brenner MB. Distinct iNKT cell populations use IFNgamma or ER stress-induced IL-10 to control adipose tissue homeostasis. Cell Metab. 2020;32:243–58.
Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes. 2009;58:2525–35.
Dagdeviren S, Jung DY, Friedline RH, Noh HL, Kim JH, Patel PR, et al. IL-10 prevents aging-associated inflammation and insulin resistance in skeletal muscle. FASEB J. 2017;31:701–10.
Van Exel E, Gussekloo J, de Craen AJ, Frölich M, Bootsma-Van Der Wiel A, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes. 2002;51:1088–92.
Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön MR, Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes. 2005;113:534–7.
Zhang J, Deng Z, Jin L, Yang C, Liu J, Song H, Han W, Si Y. Spleen-derived anti-inflammatory cytokine IL-10 stimulated by adipose tissue-derived stem cells protects against type 2 diabetes. Stem Cells Dev. 2017;26:1749–58.
Welsh P, Murray HM, Ford I, Trompet S, de Craen AJ, Jukema JW, et al. Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol. 2011;31:2338–44.
Francisco CO, Catai AM, Moura-Tonello SCG, Arruda LCM, Lopes SLB, Benze BG, et al. Cytokine profile and lymphocyte subsets in type 2 diabetes. Braz J Med Biol Res. 2016;49:e5062.
Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018;8:1031–63.
Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab. 2012;38:183–91.
Li S, Shin HJ, Ding EL, VanDam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179–88.
Su H, Lau WB, Ma XL. Hypoadiponectinaemia in diabetes mellitus type 2: molecular mechanisms and clinical significance. Clin Exp Pharmacol Physiol. 2011;38:897–904.
Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–9.
Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–9.
Borges MD, Franca EL, Fujimori M, Silva SMC, de Marchi PGF, Deluque AL, et al. Relationship between proinflammatory cytokines/chemokines and adipokines in serum of young adults with obesity. Endocr Metab Immune Disord Drug Targets. 2018;18:260–7.
Selthofer-Relatić K, Radić R, Stupin A, Šišljagić V, Bošnjak I, Bulj N, et al. Leptin/adiponectin ratio in overweight patients - gender differences. Diab Vasc Dis Res. 2018;15:260–2.
Kumari R, Kumar S, Kant R. An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome. Diab Metab Syndr. 2019;13:2409–17.
Kopf S, Oikonomou D, von Eynaten K, Kiesser M, Zdunek D, Hess G, et al. Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes. Acta Diabetol. 2014;51:479–89.
Alnaggar ARLR, Sayed M, El-Deena KE, Gomaa M, Hamed Y. Evaluation of serum adiponectin levels in diabetic nephropathy. Diab Metab Syndr. 2019;13:128–31.
Przybyciński J, Dziedziejko V, Puchałowicz K, Domański L, Pawlik A. Adiponectin in chronic kidney disease. Int J Mol Sci. 2020;21:9375.
Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and adipoR1 regulate PGC-1a and mitochondria by Ca2+ and AMPK/SIRT1. Nature. 2010;464:1313–9.
Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55–63.
Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol. 2006;574:41–53.
Li X, Zhang D, Vatner DF, Goedeke L, Hirabara SM, Zhang Y, et al. Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice. Proc Natl Acad Sci U S A. 2020;117:32584–93.
Luo S, Lei H, Liu Q. Correlation between serum adiponectin and risk factors in patients with coronary artery disease. Clin Lab. 2013;59:121–6.
Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: a promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7:57–62.
Brolin EB, Agewall S, Cederlund K, Ekenbäck C, Henareh L, Malmqvist K, et al. Plasma biomarker levels and non obstructive coronary artery disease determined by coronary computed tomography angiography. Clin Physiol Funct Imaging. 2018;38:246–53.
Goeller M, Achenbach S, Marwan M, Doris MK, Cadet S, Commandeur F, et al. Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects. J Cardiovasc Comput Tomogr. 2018;12:67–73.
Takahashi Y, Watanabe R, Sato Y, Ozawa N, Kojima M, Watanabe-Kominato K, et al. Novel phytopeptide osmotin mimics preventive effects of adiponectin on vascular inflammation and atherosclerosis. Metabolism. 2018;83:128–38.
Ahmad A, Ali T, Kim MW, Khan A, Jo MH, Rehman SU, et al. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARalpha signaling in ob/ob and db/db transgenic mouse models. Metabolism. 2019;90:31–43.
Deng G, Long Y, Yu YR, Li MR. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes. 2010;34:165–71.
Ohashi K, Parker JL, Ouchi N, Higuchi A, Vita JA, Gokce N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem. 2010;285:6153–60.
Polito R, Nigro E, Messina A, Monaco ML, Monda V, Scudiero O, et al. Adiponectin and orexin-A as a potential immunity link between adipose tissue and central nervous system. Front Physiol. 2018;9:982.
Wilk S, Scheibenbogen C, Bauer S, Jenke A, Rother M, Guerreiro M, et al. Adiponectin is a negative regulator of antigen-activated T cells. Eur J Immunol. 2011;41:2323–32.
Wilk S, Jenke A, Stehr J, Yang CA, Bauer S, Goldner K, et al. Adiponectin modulates NK-cell function. Eur J Immunol. 2013;43:1024–33.
Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the funcions of macrophages. Blood. 2000;96:1723–32.
Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression inhuman macrophages. Circulation. 2004;109:2046–9.
Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–9.
Koch CE, Lowe C, Legler K, Benzler J, Boucsein M, Böttiger G, et al. Central adiponectin acutely improves glucose tolerance in male mice. Endocrinology. 2014;155:1806–16.
Coope A, Milanski M, Araújo EP, Tambascia M, Saad MJ, Geloneze B, et al. AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the hypothalamus. FEBS Lett. 2008;582:1471–6.
Quaresma PG, Reencober N, Zanotto TM, Santos AC, Weissmann L, de Matos AH, et al. Pioglitazone treatment increases food intake and decreases energy expenditure partially via hypothalamic adiponectin/AdipoR1/AMPK pathway. Int J Obes. 2016;40:138–46.
Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56:714–23.
Barzilay JI, Jablonski KA, Fonseca V, Shoelson SE, Goldfine AB, Strauch C, et al. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care. 2014;37:1083–91.
Kim G, Lee YH, Yun MR, Lee JY, Shin EG, Lee BW, et al. Effects of lobeglitazone, a novel thiazolidinedione, on adipose tissue remodeling and brown and beige adipose tissue development in db/db mice. Int J Obes. 2018;42:542–51.
Li J, Xue YM, Zhu B, Pan YH, Zhang Y, Wang C, Li Y. Rosiglitazone elicits an adiponectin-mediated insulin-sensitizing action at the adipose tissue-liver axis in Otsuka Long-Evans Tokushima fatty rats. J Diabetes Res. 2018;2018:4627842.
Bril F, Kalavalapalli S, Clark VC, Lomonaco R, Soldevila-Pico C, Liu IC, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16:558–66.e2.
Giacalone G, Tsapis N, Mousnier L, Chacun H, Fattal E. PLA-PEG Nanoparticles improve the anti-inflammatory effect of rosiglitazone on macrophages by enhancing drug uptake compared to free rosiglitazone. Materials. 2018;11:1845.
Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovasc Diabetol. 2016;15:153.
Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E146–50.
Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1beta antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 2013;39:524–31.
Huang J, Yang Y, Hu R, Chen L. Anti-interleukin-1 therapy has mild hypoglycaemic effect in type 2 diabetes. Diabetes Obes Metab. 2018;20:1024–8.
Shen HH, Peterson SJ, Bellner L, Choudhary A, Levy L, Gancz L, et al. Cold-pressed nigella sativa oil standardized to 3% thymoquinone potentiates omega-3 protection against obesity-induced oxidative stress, inflammation, and markers of insulin resistance accompanied with conversion of white to beige fat in mice. Antioxidants. 2020;9:489.
Hunsche C, Hernandez O, Gheorghe A, Díaz LE, Marcos A, De la Fuente M. Immune dysfunction and increased oxidative stress state in diet-induced obese mice are reverted by nutritional supplementation with monounsaturated and n-3 polyunsaturated fatty acids. Eur J Nutr. 2018;57:1123–35.
Tousoulis D, Plastiras A, Siasos G, Oikonomou E, Verveniotis A, Kokkou E, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis. 2014;232:10–6.
Rylander C, Sandanger TM, Engeset D, Lund E. Consumption of lean fish reduces the risk of type 2 diabetes mellitus: a prospective population based cohort study of Norwegian women. PLoS One. 2014;9:e89845.
Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Wisnewsky J, et al. T cell-derived IL-22 amplifies IL-1-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes. 2014;63:1966–77.
Further Reading
Bai Y, Sun Q. Macrophage recruitment in obese adipose tissue. Obes Rev. 2015;16:127–36.
Böni-Schnetzler M, Häuselmann SP, Dalmas E, Meier DT, Thienel C, Traub S, et al. Beta cell-specific deletion of the IL 1 receptor antagonist impairs beta cell proliferation and insulin secretion. Cell Rep. 2018;22:1774–86.
Eljaafari A, Robert M, Chehimi M, Chanon S, Durand C, Vial G, et al. Adipose tissue–derived stem cells from obese subjects contribute to inflammation and reduced insulin response in adipocytes through differential regulation of the Th1/Th17 balance and monocyte activation. Diabetes. 2015;64:2477–88.
Ferrante AW Jr. The immune cells in adipose tissue. Diabetes Obes Metab. 2013;15:34–8.
Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity. 2015;23:512–8.
Ip B, Cilfone N, Belkina AC, DeFuria J, Jagannathan-Bogdan M, Zhu M, et al. Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNF-α production. Obesity. 2016;24:102–12.
Olson NC, Doyle MF, de Boer IH, Huber SA, Jenny NS, Kronma RA, et al. Associations of circulating lymphocyte subpopulations with type 2 diabetes: cross-sectional results from the multi-ethnic study of atherosclerosis (MESA). PLoS One. 2015;10:e0139962. https://doi.org/10.1371/journal.pone.0139962.
Pirola L, Ferraz JC. Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity. World J Biol Chem. 2017;8:120–8.
Wu J, Wu D, Zhang L, Lin C, Liao J, Xie R, et al. NK cells induce hepatic ER stress to promote insulin resistance in obesity through osteopontin production. J Leukoc Biol. 2020;107:589–96.
Sung KC, Lee MY, Kim YH, Huh JH, Kim JY, Wild SH, et al. Obesity and incidence of diabetes: effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver. Atherosclerosis. 2018;275:50–7.
Viel S, Besson L, Charrier E, Marçais A, Disse E, Bienvenu J, et al. Alteration of natural killer cell phenotype and function in obese individuals. Clin Immunol. 2017;177:12–7.
Lu Y, Ma J, Zhao J, Song Z, Zhou C, Liu X, et al. The Role of MKP-5 in Adipocyte-macrophage interactions during obesity. Obes Facts. 2020;13:86–101.
Margaryan S, Kriegova E, Fillerova R, Smotkova Kraiczova V, Manukyan G. Hypomethylation of IL1RN and NFKB1 genes is linked to the dysbalance in IL1beta/IL-1Ra axis in female patients with type 2 diabetes mellitus. PLoS One. 2020;15:e0233737.
Koppaka S, Kehlenbrink S, Carey M, Li W, Sanchez E, Lee DE, et al. Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. Diabetes. 2013;62:1843–54.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Glossary
- Adipokine
-
A cytokine or hormone that is secreted by adipose tissue
- Chemokines
-
Are signaling proteins secreted by cells, whose main function is to act as a chemoattractant to guide the migration of near cells. They are implicated in various diseases, such as cancer, autoimmune disorders, and diabetes
- Cytokine
-
Small proteins secreted and released by cells, they have a specific effect on the interactions and communications between cells
- Diet-induced obesity (DIO)
-
Obesity mouse model induced by high-fat diet
- FA
-
A carboxylic acid with aliphatic chains of 4–28 carbons, which can be esterified with glycerol to form triacylglycerols, the main stored form of lipids
- HFD
-
High-fat diet
- IgG, IgM
-
Are members of immunoglobulin (Ig) superfamily, they are ubiquitously present in several cells and tissues of vertebrates and share structural homology with cell adhesion molecules and some cytokines
- Innate immune cells
-
Are white blood cells that mediate innate immunity and include basophils, dendritic cells, eosinophils, mast cells, monocytes, macrophages, neutrophils, and natural killer cells
- Mitogen-Activated Protein Kinase (MAPK)
-
A mammalian Ser/Thr protein kinase
- NF-κB
-
Nuclear factor-κB is a ubiquitous transcription factor involved in the control of processes, such as immune and inflammatory responses, developmental, cellular growth, and apoptosis. The NF-κB pathway has been considered as proinflammatory signaling pathway, based on the role of NF-κB in the expression of proinflammatory genes including cytokines, chemokines, and adhesion molecules
- Omental adipose tissue
-
The fat depot found within the peritoneum, in close association with stomach and other internal organs
- PPAR-γ
-
Peroxisome proliferator-activated receptor gamma is an essential transcription regulator of the adipocyte differentiation and is required for mature adipocyte function
- Salicylates
-
A group of derivatives of salicylic acid, including aspirin and acetylsalicylic acid, which are widely used as analgesics, and anti-inflammatory medicaments
- Thiazolinediones
-
Antidiabetic drugs used therapeutically, which are known to be high-affinity ligand activators of PPARs
- White adipose tissue (WAT)
-
The predominant fat storage tissue in animals, consisting mostly of adipocytes but also other cell types as mast cells and macrophages
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
García-Macedo, R., de los Ángeles Fortis, M. (2023). The Immune System and Inflammation in Type 2 Diabetes. In: Rodriguez-Saldana, J. (eds) The Diabetes Textbook. Springer, Cham. https://doi.org/10.1007/978-3-031-25519-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-031-25519-9_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-25518-2
Online ISBN: 978-3-031-25519-9
eBook Packages: MedicineMedicine (R0)